Genocea Biosciences Inc. (NASDAQ:GNCA) CFO Jonathan Poole acquired 7,000 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The stock was purchased at an average cost of $3.34 per share, for a total transaction of $23,380.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Genocea Biosciences Inc. (NASDAQ:GNCA) opened at 4.45 on Monday. The company has a 50-day moving average of $4.17 and a 200-day moving average of $4.43. The company’s market cap is $126.09 million. Genocea Biosciences Inc. has a 12 month low of $2.56 and a 12 month high of $8.07.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.01. Genocea Biosciences had a negative return on equity of 54.25% and a negative net margin of 5,121.17%. Analysts predict that Genocea Biosciences Inc. will post ($1.64) EPS for the current year.

A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a report on Thursday, November 3rd. FBR & Co reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Genocea Biosciences in a report on Wednesday, October 5th. Finally, Piper Jaffray Cos. dropped their price objective on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, September 29th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $12.35.

Large investors have recently made changes to their positions in the company. Alpine Partners VI LLC bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $120,000. TFS Capital LLC bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $133,000. Northern Trust Corp increased its stake in shares of Genocea Biosciences by 24.3% in the third quarter. Northern Trust Corp now owns 34,636 shares of the company’s stock valued at $177,000 after buying an additional 6,763 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $143,000. Finally, Ameriprise Financial Inc. bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $156,000. Institutional investors and hedge funds own 58.65% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

5 Day Chart for NASDAQ:GNCA

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.